Early versus delayed Blad‑Care (hyaluronic acid + chondroitin) during BCG therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Patients with non‑muscle‑invasive bladder cancer receiving intravesical BCG are randomized to receive intravesical Blad‑Care either early during BCG induction or delayed after induction. Blad‑Care contains hyaluronic acid and chondroitin sulfate intended to restore the bladder glycosaminoglycan (GAG) layer and protect the urothelium. The study prospectively compares bladder irritation symptoms, adverse events, and BCG treatment adherence between the two timing strategies. The multicenter trial at Korean sites seeks to identify whether early administration reduces BCG‑induced cystitis without compromising oncologic therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged ≥19 years
* Histologically confirmed non-muscle-invasive bladder cancer
* Candidates for intravesical BCG therapy
* Negative urine culture prior to BCG therapy
* Ability to provide written informed consent

Exclusion Criteria:

* Hypersensitivity to components of Blad-Care
* Contraindication to BCG therapy
* Neurogenic bladder or significant urinary tract abnormalities
* Severe renal dysfunction
* Any condition considered unsuitable for study participation by the investigator

Where it's running

• Kyung Hee University Hospital
  Seoul, Dongdaemun-gu, South Korea Recruiting

Study contacts

• Principal investigator: Chunwoo Lee — Kyung Hee University Hospital
• Study coordinator: Chunwoo Lee, M.D., Ph.D.
• Email: lcw200@hanmail.net
• Phone: +8229588897

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inactivated UPEC-FimON for Bladder Cancer After BCG or Intravesical Therapy Failure

  This phase 1 study tests whether intravesical doses of inactivated UPEC-FimON are safe and tolerable in adults with non-muscle invasive bladder cancer that progressed after BCG or intravesical therapy.

  Recruiting at 3 sites Phase 1 Hopec Pharma · Kfar Saba, Central District and 2 other locations · NCT07881666

• Alpha1H before bladder tumor surgery in low/intermediate risk non-muscle-invasive bladder cancer

  This trial tests whether putting Alpha1H directly into the bladder before standard surgery helps prevent cancer from coming back or getting worse in adults with low- to intermediate-risk non-muscle-invasive bladder cancer.

  Recruiting Phase 3 Hamlet Pharma AB · Prague · NCT07804056

• Understanding how high-risk non-muscle-invasive bladder cancer is diagnosed and cared for in Portugal

  This study looks at how patients with high-risk non-muscle-invasive bladder cancer have been diagnosed and treated in regular care in Portugal.

  Recruiting Janssen-Cilag Farmaceutica Ltda. · Lisbon · NCT07784387

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• Real-world look at high-risk non-muscle-invasive bladder cancer after BCG in Korea

  This study tests how people with high-risk non-muscle-invasive bladder cancer fare after BCG therapy in real-world clinical settings in Korea.

  Recruiting Janssen Korea, Ltd., Korea · Suwon · NCT07735793

• Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer

  This trial tests whether combining enfortumab vedotin with pembrolizumab can help people with non-metastatic muscle-invasive bladder cancer keep their bladder and control the cancer better than standard concurrent chemoradiotherapy.

  Recruiting at 29 sites Phase 3 Astellas Pharma Inc · Little Rock, Arkansas and 28 other locations · NCT07566156

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.